On 9 October 2025, the VERBA LEGAL team successfully completed advisory services for the additional share issue of PJSC Ozon Pharmaceuticals (“the Company”), a leading Russian pharmaceutical group. This stage marked the conclusion of the secondary public offering (“SPO”) initiated by the Company on 20 June 2025, during which VERBA LEGAL also provided advisory support.

The transaction was executed as a top-up, involving capital raising in two phases: the SPO (20 June 2025) and the additional issue (placement completed on 9 October 2025).

Proceeds raised during the SPO were used by Ozon LLC to repurchase shares in order to repay a securities loan to the Company’s founder. Consequently, the number of shares held by the founder was restored to the pre-SPO level, while the Company received cash funds.

During the additional issue, 3.2 million shares were also placed among the Company’s shareholders exercising their pre-emptive rights. This allowed shareholders to maintain their stakes in the Company’s authorised capital and acquire the additional shares at the SPO price.

The VERBA LEGAL team working on the project included Partner Aleksandr Kuznetsov, Senior Associate Anna Sidorenko, Associate Ivan Dubrovskiy, and Senior Associate of the Tax Advisory & Disputes practice Andrey Sheptiy.